Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav

The Food and Drug Administration has approved Jazz Pharmaceuticals' new drug application for Xywav, a new sleep disorder drug. Xywav was approved by the FDA, Tuesday night, to treat cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Jazz stock was up nearly 4.6% to $110.34 per share in early morning trading. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news